Evidence map›Paper›PMID 40610462›Full record

ArticleNPJ Parkinson's disease2025

Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort.

Ruwani S Wijeyekoon, Marta Camacho, David Bäckström, Lars Forsgren, Rachael A Lawson, Alison J Yarnall, Angus D Macleod, Carl E Counsell, Ole-Bjørn Tysnes, Guido Alves and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruwani S WijeyekoonDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. rsw27@cam.ac.uk.
Marta CamachoDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
David BäckströmDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Lars ForsgrenDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Rachael A LawsonTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Alison J YarnallTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Angus D MacleodInstitute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.ORCID http://orcid.org/0000-0002-6284-4239
Carl E CounsellInstitute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
Ole-Bjørn TysnesDepartment of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway.
Guido AlvesCenter for Movement Disorders, Center for Brain Health, Stavanger University Hospital, Stavanger, Norway.ORCID http://orcid.org/0000-0003-0630-2870
Jodi Maple-GrødemCenter for Movement Disorders, Center for Brain Health, Stavanger University Hospital, Stavanger, Norway.ORCID http://orcid.org/0000-0001-7142-0078
Roger A BarkerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-8843-7730
Caroline H Williams-GrayDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2648-9743
Parkinson’s Incidence Cohorts Collaboration

Funding

CUH | Addenbrooke's Charitable Trust, Cambridge University Hospitals (Addenbrooke's Charitable Trust, Cambridge University Hospitals NHS Foundation Trust) RG77199DH | National Institute for Health Research (NIHR) NF-SI-0616-10011Norges Forskningsråd (Research Council of Norway) 287842Parkinson's UK F-1801RCUK | Medical Research Council (MRC) MR/R007446/1; MR/W029235/1Wellcome Trust
6 · The paper itself

Abstract

Beta-adrenoceptor-blockers and agonists have been associated with an increased and decreased risk of Parkinson's disease (PD), respectively. We aimed to investigate whether these medications are linked to clinical heterogeneity and progression in PD. Longitudinal data from the Parkinson's Incident Cohorts Collaboration (n = 1107) were analysed. Baseline clinical status and progression to Hoehn & Yahr stage 3 (H&Y3) or dementia were compared in beta-blocker or beta-agonist users versus non-users of each drug. Baseline motor and cognitive variables were similar in beta-blocker users (n = 195) versus non-users and beta-agonist users (n = 68) versus non-users, following adjustment for relevant confounders. Beta-blocker users (n = 156) progressed faster to H&Y3 (p = 0.002), accounting for relevant confounders (Hazard Ratio (HR) = 1.538; p = 0.011), while beta-agonist users (n = 54) progressed similarly to non-users. Neither drug was associated with progression to dementia. These findings support the possibility that beta-adrenoceptor drugs may have potential in modifying aspects of PD progression. Further investigation is essential to identify any causative component in the relationship.

Identifiers

PMID40610462
PMCPMC12229619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.